Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put GlaxoSmithKline GSK stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, GlaxoSmithKline has a trailing twelve months PE ratio of 13.1, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.4. If we focus on the long-term PE trend, GlaxoSmithKline’ current PE level puts it below its midpoint of 14.8 over the past five years. Moreover, the current level stands below the highs for the stock, suggesting that it can be a solid entry point.
Further, the stock’s PE also compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 20.4. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that GlaxoSmithKline has a forward PE ratio (price relative to this year’s earnings) of 13.9, so it is fair to expect an increase in the company’s share price in the near term.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, GlaxoSmithKline has a P/S ratio of about 2.2. This is lower than the S&P 500 average, which comes in at 3.2 right now. Also, as we can see in the chart below, this is below the highs for this stock in particular over the past few years.
Broad Value Outlook
In aggregate, GlaxoSmithKline currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes GlaxoSmithKline a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for GlaxoSmithKline is 2.0, a level that is marginally lower than the industry average of 2.1. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 9.8, which is better than the industry average of 11.5. Clearly, GSK is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though GlaxoSmithKline might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of F. This gives GSK a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been stable. The current year has seen two upward revisions and two downward revisions in the past sixty days, while the next year estimate has seen one upward and one downward revision in the same time period.
As a result, the current year consensus estimate has risen 0.7% in the past two months, while the estimate for the next year has increased 2.4%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
GlaxoSmithKline plc Price and Consensus
GlaxoSmithKline plc Price and Consensus | GlaxoSmithKline plc Quote
Despite the bullish trend, the stock has just a Zacks Rank #3 (Hold), which is why we are looking for in-line performance from the company in the near term.
GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (bottom 44% of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the broader industry has underperformed the market at large, as you can see below:
So, value investors might want to wait for the broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
To read this article on Zacks.com click here.